Hutchin Hill Capital’s United Therapeutics UTHR Stock Holding History

Hutchin Hill Capital’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,500	Closed	-$203K	–	1056
2017 Q1	$203K	Buy	+1,500	New	+$227K	0.01%	854
2015 Q3	–	Sell	-11,100	Closed	-$1.93M	–	758
2015 Q2	$1.93M	Buy	+11,100	New	+$2M	0.05%	330
2015 Q1	–	Sell	-3,000	Closed	-$388K	–	800
2014 Q4	$388K	Buy	+3,000	New	+$387K	0.01%	478
2014 Q3	–	Sell	-51,300	Closed	-$4.54M	–	726
2014 Q2	$4.54M	Buy	51,300 +25,300	+97%	+$2.43M	0.21%	81
2014 Q1	$2.44M	Buy	+26,000	New	+$2.66M	0.13%	139

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hutchin Hill Capital's UTHR Position: Q2 2017 in Review

Hutchin Hill Capital sold out of United Therapeutics (UTHR) in Q2 2017, closing a stake of 1,500 shares — an estimated $203K sold.

Hutchin Hill Capital first reported a position in UTHR in Q1 2014 and held it in 5 quarters. The position peaked at $4.54M in Q2 2014. 373 funds tracked by Wall St. Rank hold UTHR as of Q2 2017.

Hutchin Hill Capital reported no remaining United Therapeutics position as of Q2 2017 after selling out during the quarter.
Hutchin Hill Capital sold 1,500 United Therapeutics shares in Q2 2017, an estimated $203K.
Hutchin Hill Capital first reported a position in United Therapeutics in Q1 2014 and held it in 5 quarters.
Hutchin Hill Capital's United Therapeutics position peaked at $4.54M in Q2 2014.
373 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2017.

Based on Hutchin Hill Capital's 13F filing for Q2 2017, filed 14 Aug 2017.